What is the Share Price of Venus Remedies Ltd?
- Answer Field
-
The share price of Venus Remedies Ltd for NSE is ₹ 302.85 and for BSE is ₹ 306.2.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, VENUS REMEDIES LIMITED share price is currently at ₹ 302.85, which is down by ₹ -8.69 from its previous closing. Today, the stock has fluctuated between ₹ 300.20 and ₹ 316.40. Over the past year, VENUS REMEDIES LIMITED has achieved a return of -7.56 %. In the last month alone, the return has been -4.23 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 172.54 |
Operating Expense | 154.83 |
Net Profit | 24.08 |
Net Profit Margin (%) | 13.95 |
Earnings Per Share (EPS) | 18.02 |
EBITDA | 34.56 |
Effective Tax Rate (%) | 17.98 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc.
The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as 'WHO-GMP' as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc.
In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox-3000,Paroxin-3000,Pisa-3000,Mical,Ronid,Dexolyte and Detox.
The year 2005-06 saw many new milestone achievements by the Company like commercial operation of its most modern and techno-savvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, German-GMP certified pharmaceutical unit at Werne, Germany, launch of its second R&D Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well.
The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 2006-07. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the 'Tobracef' brand in 2008-09. It launched its anti-cancer drug 'Docetaxel' in Europe by end 2011, launched ACHNIL, the once-a-day pain management therapy in India in 2011; launched 'Cytomib', a first-time therapy against blood cancer in 2011; launched 'Taxedol' in three
strengths-20 mg, 80 mg and 120 mg in 2012.
In 2013, the Company established pre-clinical proof of concept for its Drug -Protein-Polymer- Conjugate (DPPC); introduced Ready-to-Use a Single Vial Taxedol in India; launched 'Trois', a miracle nano-emulsion for arthritic Pain; launched 'Elores' - CSE 1034, a US patent protected product in India, launched its first OTC product 'Ezenus'.
In 2014, the Company launched ELORES, an antibiotic to fight superbugs'. In 2021-22, it launched first product in the consumer healthcare space, R3SET - a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decision-making, a
BI tool like Tableau was also launched in 2022.
The share price of Venus Remedies Ltd for NSE is ₹ 302.85 and for BSE is ₹ 306.2.
The market cap of Venus Remedies Ltd for NSE is ₹ 4,04.81 Cr. and for BSE is ₹ 4,09.29 Cr. as of now.
The 52 Week High and Low of Venus Remedies Ltd for NSE is ₹ 427.90 and ₹ 270.25 and for BSE is ₹ 427.30 and ₹ 272.20.
You can trade in Venus Remedies Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been -7.56%.
Venus Remedies Ltd share price is for NSE ₹ 302.85 & for BSE ₹ 306.2 as on Apr 30 2025 03:30 PM.
The market cap of Venus Remedies Ltd for NSE ₹ 4,04.81 & for BSE ₹ 4,09.29 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Venus Remedies Ltd share is 8.10.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Venus Remedies Ltd share is 392.44.
You can trade in Venus Remedies Ltd shares with Bajaj Broking by opening a demat account.
To buy Venus Remedies Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Venus Remedies Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found